MSD Korea exceeded KRW 20 billion annual sales for hyperlipidemia complex Atozet

Published: 2016-12-08 15:45:55

Updated: 2016-12-08 16:10:55

MSD Korea(CEO Avi BenShoshan) announced on the 6^th that the hyperlipidemia therapy ‘Atozet(generic name: ezetimibe/atorvastatin)’ made annual sales of KRW 20 billion and recorded the top sales in the statin+ezetimibe complex market.

The market of statin+ezetimibe complex for hyperlipidemia treatment consists solely of the complex launched in 2005, Vytorin(ezetimibe/simvastatin), but after the ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.